What is 4D Molecular Therapeutics, Inc.'s Shariah compliance score?

4D Molecular Therapeutics, Inc.'s (FDMT) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does 4D Molecular Therapeutics, Inc. pass AAOIFI screening?

4D Molecular Therapeutics, Inc. (FDMT) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (FDMT: 4.3%), (3) interest-bearing deposits below 30% (FDMT: 81.8%), and (4) prohibited income below 5% (FDMT: 39871.4%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for 4D Molecular Therapeutics, Inc. stock?

4D Molecular Therapeutics, Inc. (FDMT) has a non-permissible income ratio of 39871.43%. Muslim investors should purify this percentage of any dividends received and capital gains realized from FDMT shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen 4D Molecular Therapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for 4D Molecular Therapeutics, Inc. (FDMT) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about FDMT's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is 4D Molecular Therapeutics, Inc. (FDMT) halal? Not Halal. Based on AAOIFI screening, 4D Molecular Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

FDMT: Is 4D Molecular Therapeutics, Inc. Halal?

Not Halal

4D Molecular Therapeutics, Inc.

NASDAQHealthcareUS

$9.27

-4.53%

AvoidBorderlineClean

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 18, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap4.3% / 30.0%

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 18, 2026Fiscal: Q1 2026Source: EDGAR

Financial Overview

Market Cap

484.6M

Price

$9.27

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track FDMT and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. (FDMT) halal to invest in?

4D Molecular Therapeutics, Inc. (FDMT) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did 4D Molecular Therapeutics, Inc. get a F compliance rating?

4D Molecular Therapeutics, Inc. (FDMT) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 4.3% (limit 30%); interest-bearing deposits of 81.8% (limit 30%); prohibited income of 39871.43% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change 4D Molecular Therapeutics, Inc.'s Shariah verdict?

4D Molecular Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is 4D Molecular Therapeutics, Inc. re-screened for Shariah compliance?

4D Molecular Therapeutics, Inc. (FDMT) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 18, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.